Medicare’s standard Part D drug deductible will climb to $700 in 2027, up from $615 this year, the most a beneficiary can be asked to pay out of pocket before prescription coverage kicks in. It is not the only number moving higher: the base premium that anchors most drug plans is rising too, and federal officials are ending a program that had been quietly holding some premiums down. For the tens of millions of older Americans who count on Part D, the practical message is to expect a bigger bill and to shop carefully this fall.
The 2027 Part D numbers that matter
The figures come straight from the government’s annual drug-plan release. According to the official CY2027 Part D announcement, the standard deductible rises to $700 for 2027, an $85 increase over the $615 in effect for 2026. The deductible is the amount a beneficiary pays first, before the plan begins sharing drug costs, so a higher figure means more spending comes out of pocket at the start of the year.
The base beneficiary premium — the benchmark used to set what enrollees pay each month — is increasing to $41.33 for 2027, up from $38.99 this year. That is roughly a 6 percent rise, the maximum increase permitted under the statutory limits that govern the base premium through the end of the decade. Individual plan premiums are built on top of that benchmark, which is why the increase ripples across the market rather than hitting a single plan.
There is one figure moving in retirees’ favor. The annual out-of-pocket cap on covered prescriptions rises to $2,400 in 2027, up from $2,100. Once a beneficiary’s spending reaches that ceiling, they pay nothing more for covered drugs for the rest of the year — a hard limit that offers real protection to anyone facing high-cost medications, even as the deductible and base premium climb.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
Why most plans are likely to cost more
Beyond the headline deductible, the structure underneath Part D premiums is shifting. In its July announcement, the government set the year’s national average bid and confirmed it is winding down a temporary premium-stabilization arrangement that had been used to blunt increases in stand-alone drug plans. As that support fades, the underlying costs that plans have been absorbing are more likely to reach enrollees in the form of higher monthly premiums.
That combination — a larger deductible, a higher base premium, and less of the behind-the-scenes cushioning that held premiums flat — is why most beneficiaries should plan on paying more next year, not less. The out-of-pocket cap softens the blow for the sickest and highest-spending enrollees, but it does nothing for the far larger group whose costs land in the deductible and monthly-premium range.
What retirees can do before open enrollment
None of these numbers means a beneficiary is stuck with a bad deal, because Part D is re-priced every year and plans reshuffle their premiums, deductibles and drug lists each fall. The single most valuable step is to review coverage during Medicare’s open enrollment window, which runs from October 15 through December 7, and to compare the specific plan that fits a person’s own prescriptions rather than assuming last year’s choice is still the cheapest.
Plans change which drugs they cover and how they tier them from one year to the next, so a medication that was inexpensive in 2026 can jump a tier in 2027, and a different plan may cover it for far less. Running current prescriptions through the plan finder — or asking a trusted counselor to do it — is the difference between paying the higher deductible on top of an ill-fitting plan and finding one that offsets part of the increase.
The larger reality is that Part D costs are drifting upward across the board, and the 2027 figures confirm the trend rather than reverse it. A retiree cannot control the $700 deductible or the higher base premium, but choosing the plan that best matches actual drug use remains the one lever that reliably keeps the total bill in check — and the only one that resets with each open enrollment.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
